Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1/1b Study of RNDO-564 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer and Other Solid Tumors Associated With Nectin-4 Expression

NCT07218003 is registered in ClinicalTrials.gov with Rondo Therapeutics as lead sponsor.

NCT NCT07218003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07218003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1/1b Study of RNDO-564 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer and Other Solid Tumors Associated With Nectin-4 Expression
Lead sponsor
Rondo Therapeutics
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
November 17, 2025
Completion date
March 31, 2029
Enrollment
149 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cervical cancer, esophageal squamous cell cancer, gastric cancer, gastroesophageal junction (gej) adenocarcinoma, head and neck squamous cell cancer, non small cell lung cancer, solid tumors (phase 1), triple negative breast cancer (tnbc), urothelial carcinoma bladder